4.77
전일 마감가:
$4.35
열려 있는:
$4.39
하루 거래량:
239.62K
Relative Volume:
0.17
시가총액:
$91.59M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+77.07%
1개월 성능:
+423.33%
6개월 성능:
+309.57%
1년 성능:
+0.00%
Citius Oncology Inc Stock (CTOR) Company Profile
명칭
Citius Oncology Inc
전화
(908) 967-6677
주소
11 COMMERCE DRIVE, CRANFORD
CTOR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CTOR
Citius Oncology Inc
|
4.71 | 91.59M | 0 | 0 | 0 | 0.00 |
![]()
RGC
Regencell Bioscience Holdings Ltd
|
16.00 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
![]()
ZTS
Zoetis Inc
|
155.29 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.34 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.45 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-27 | 개시 | Maxim Group | Buy |
Citius Oncology Inc 주식(CTOR)의 최신 뉴스
Citius Oncology prepares for lymphoma treatment launch in 2025 By Investing.com - Investing.com Nigeria
Citius Oncology On Track to Launch Lymphir in US in H2 - MarketScreener
Citius Oncology prepares for lymphoma treatment launch in 2025 - Investing.com
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 - StreetInsider
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - The Victoria Advocate
Citadel Advisors LLC Makes New $26,000 Investment in Citius Oncology, Inc. (NASDAQ:CTOR) - Defense World
After Major Oncology Conference, All Eyes Turn to Industry Innovation - Cantech Letter
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - Longview News-Journal
Citius Pharmaceuticals Secures $15.8M Strategic Financing: LYMPHIR Commercial Launch Gets Green Light - Stock Titan
Citius Oncology partners with Cardinal Health for LYMPHIR distribution By Investing.com - Investing.com South Africa
Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health - MarketScreener
Citius Oncology Signs US Distribution Deal With Cardinal Health for Lymphir - marketscreener.com
Cardinal Health (CAH) Partners with Citius Oncology for LYMPHIR Distribution | CAH Stock News - GuruFocus
Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR - Nasdaq
Citius Oncology stock soars on distribution deal By Investing.com - Investing.com South Africa
Citius Oncology stock soars on distribution deal - Investing.com
Citius Oncology partners with Cardinal Health for LYMPHIR distribution - Investing.com
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health | CTXR Stock News - GuruFocus
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health - Yahoo Finance
Citius Oncology (NASDAQ:CTOR) Trading Up 3.4% – Here’s Why - Defense World
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Maxim Downgrades Citius Oncology to Hold From Buy - marketscreener.com
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Laun - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Launch | CTXR Stock News - GuruFocus
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Citius Pharmaceuticals Reports Critical Cash Position, Advances FDA-Approved LYMPHIR Launch Strategy - Stock Titan
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - Yahoo Finance
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | CTXR Stock News - GuruFocus
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - PR Newswire
Citius Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
Citius Oncology IncReceives Nasdaq Notice For Bid Price Non-ComplianceSEC Filing - marketscreener.com
Citius Oncology (NASDAQ:CTOR) Trading 6.3% Higher – Still a Buy? - Defense World
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Citius Oncology Inc (NASDAQ: CTOR) Is On The Fall - stocksregister.com
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com India
Citius Oncology (NASDAQ:CTOR) Shares Up 39.8% – Still a Buy? - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
3 Penny Stocks to Watch Now, 4/1/25 - TipRanks
Why Citius Oncology Inc. Stock Spiked Over 7%? - timothysykes.com
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Citius Oncology Inc (CTOR) 재무 분석
Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):